长春高新产品调价第四季预亏10亿 年投超20亿研发欲摆脱生长激素依赖 独家深度推荐： 小米起诉自媒体获赔500万 侵权账号实控人是蔚来李斌？ 海南瑞泽5年亏25.6亿 张海林家族质押率超60%存平仓风险 中国中免跌停单日市值蒸发190亿 回应证实失去上海机场部分经营权 294家A股公司发"春节红包"3898亿 五粮液分红额居前十近五年累派768亿 资本大佬李兆廷被拘留已罚款5.9亿 东旭系"独苗"嘉麟杰10年仅分红988万 因欣旺达产品质量问题 极氪召回超3.8万辆汽车 福石控股四年亏1.9亿 控股股东质押率100%未补偿业绩被罚 西南证券拟定增60亿国资认购25亿 盈利最高预增57% 亚辉龙蹭脑机热点遭警示后又被立案 主业和"炒股"双失利 容百科技1200亿订单变950万罚单 信披失真董事长白厚善被罚300万 中国出口汽车超700万辆全球三连冠 比亚迪力争2026年海外售车130万辆 海昌智能应收账款4.5亿占营收56% 涉专利诉讼或赔1083万 智己2025年卖车8.1万辆三年未达标 刘涛就断言特斯拉存安全隐患致歉 中国神华1336亿重组审核仅6天过关 打包收购12家公司 ...

连续多日下跌的长春高新，股价罕见狂拉。 二级市场行情显示，2月25日和26日两个交易日，长春高新股价涨幅达11.4%，截至26日收盘报98.50元/ 股，总市值401.8亿元。 消息层面，长春高新2月25日公告披露，旗下子公司金赛药业GenSci141软膏境内生产药品注册临床试 验申请获国家药监局批准，适应症为改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激 素合成减少型先天性肾上腺皮质增生症及特发性原因导致的儿童小阴茎。 上述药物本次只是拿到了临床试验的批准，距离上市或还有很长的路要走。 长春高新在公告中指出，本次临床试验进程尚存在不确定性。敬请广大投资者谨慎决策，注意防范投资 风险。 据时代周报报道，长春高新相关人士表示，目前该药物只是拿到了临床试验的批准，暂未开始进行临床 研究。"上市时间还不确定，后续从临床试验、上市申报再到最终获批上市还需较长时间。" 另据智通财经，长春高新称，一切信息应以公告披露内容为准，该产品当前仅获批开展此前公告所述临 床试验，适应症需严格按照批件执行。GenSci141为一款2.2类改良型新药，目前处于临床前向临床过渡 阶段。从研发周期看，即便进展顺利，从临床到 ...

【#1支降了2325元生长激素纳入医保# #医生称生长激素副作用发生率低于3%# 】2026年1月1日起，新 版国家医保药品目录在全国范围内正式落地实施，生长激素被纳入医保报销范围。"长效针原价3225 元，医保报销后一支只要900元。"不少患儿家庭表示经济压力大大减轻。然而@扬子晚报 记者在采访 中发现，部分家长对生长激素的副作用及用药时机仍存有不少疑虑和纠结。来自温州的陈女士告诉@扬 子晚报 记者，儿子4岁时被确诊为生长激素缺乏症，医生建议注射生长激素治疗。起初，孩子使用的是 短效针剂，单支价格为1021元。按照孩子40斤的体重计算，一支药能用6天，每天都要打一针，经济压 力挺大的。"医保新政一出来，我就立马给孩子换成了长效针剂，长效针原价3225元，医保报销后一支 只要900元。每周只需要注射一次，我家孩子一支能分两次用，一年下来能省几万块。"陈女士说。治疗 效果也让她看到了希望："刚开始治疗的几个月，孩子平均每个月能长1公分，一年下来长高了11厘米， 效果很不错。" 尽管医保新政带来了实实在在的红利，但记者采访发现，部分患儿家长仍在用药的希望 与焦虑中反复挣扎，副作用如何规避、用药时机怎样把握等问题困 ...

Core Viewpoint - Changchun High-tech, known as "Northeast Medicine King," is facing a dramatic decline in performance, with a projected net profit of only 150 million to 220 million yuan for 2025, representing a year-on-year drop of over 90%, marking the worst performance in nearly two decades [1][6]. The company reported a staggering quarterly loss of nearly 1 billion yuan in Q4, with a year-on-year increase in losses of approximately 360% to 390% [1][6]. Group 1: Dependency on Single Product - The core issue behind the sharp decline in Changchun High-tech's performance is its long-standing reliance on the growth hormone business, which has been the company's profit pillar [2][7]. The net profit from its subsidiary, Jinsai Pharmaceutical, was nearly equal to the company's overall net profit in 2022 and 2023, highlighting its over-dependence [2][7]. - The inclusion of the core product, long-acting growth hormone "Jinsai Zeng," in the national medical insurance directory by the end of 2025 led to a price drop of approximately 75% for its 9mg specification, significantly eroding profit margins [2][7]. - The growth hormone market has shifted from a monopoly to intense competition, with similar products from companies like Teva and Novo Nordisk entering the market, breaking Changchun High-tech's previous technical barriers and market monopoly [2][7]. Group 2: Challenges in Transition - Recognizing the risks of putting all eggs in one basket, Changchun High-tech has been actively promoting transformation and increasing R&D investment, with R&D expenses expected to account for 20% of revenue in 2024 and a 23% year-on-year increase in R&D investment in the first three quarters of 2025 [3][8]. - However, the long and risky cycle of innovative drug development means that new products, such as the gout drug "Jin Peixin" and the cancer anorexia treatment "Mei Shiya," generated less than 160 million yuan in sales in the first three quarters of 2025, contributing minimally to overall performance [3][8]. - The company's sales expenses have been rising, with a sales expense ratio of 38.38% in the first three quarters of 2025, reflecting the need for deeper market coverage for mature products and significant resource investment for new product market education [3][8]. Group 3: Future Outlook - Industry analysis indicates that Changchun High-tech is currently in a transitional phase characterized by the "old engine losing power and the new engine not yet reaching speed" [4][9]. The impact of price reductions from medical insurance will take time to digest, and new products face multiple barriers before becoming performance pillars [4][9]. - In the short term, the company's performance may continue to be under pressure due to uncertainties in innovative drug development, underwhelming new product sales, and changes in industry policies [4][9]. - However, from a long-term perspective, as the price system for growth hormones stabilizes and market penetration improves with the support of medical insurance, this business may still provide a stable cash flow foundation for the company [4][9]. The ability to cultivate second and third growth curves through sustained high R&D investment will be crucial for Changchun High-tech to navigate the cycle and return to a growth trajectory [4][9].

Group 1 - Aihua Long faces regulatory scrutiny after being warned about its involvement in the brain-machine interface sector, leading to a formal investigation and losses in both its main business and stock trading activities [1] - Rongbai Technology's order value plummeted from 120 billion to a fine of 9.5 million due to false disclosures, with Chairman Bai Houshan fined 3 million [1] - BYD aims to sell 1.3 million vehicles overseas by 2026, contributing to China's export of over 7 million vehicles, marking a third consecutive year of global leadership in this sector [1] Group 2 - Haichang Intelligent has accounts receivable of 450 million, accounting for 56% of its revenue, and is involved in a patent lawsuit that may result in a compensation of 10.83 million [1] - Zhiji Motors has set a target of selling 81,000 vehicles by 2025 but has failed to meet its targets for three consecutive years, with CEO Liu Tao apologizing for safety concerns related to Tesla [1] - China Shenhua's restructuring plan, involving the acquisition of 12 companies, was approved in just six days, with a total value of 133.6 billion [1] Group 3 - Changchun High-tech anticipates a loss of 1 billion in the fourth quarter due to product price adjustments, while investing over 2 billion annually in R&D to reduce reliance on growth hormones [1] - Vanke's losses are expected to deepen, projecting a loss of 82 billion by 2025, with a bond extension of 6.8 billion and additional support of 2.36 billion from Shentie [1] - GAC Group has issued a rare profit warning, expecting losses between 8 billion to 9 billion, with CEO Feng Xingya reiterating the focus on three major battles for a turnaround [1] Group 4 - Nanhai Rural Commercial Bank was fined 3.8 million, with its net interest margin dropping to 1.15% after eight years of unsuccessful A-share market attempts [1] - Yuanji Food is closing one out of every three new stores, with Yuan Lianghong's wife holding shares in six supplier companies involved in related transactions worth 130 million [1] - "Cheese Queen" Chai Xiu has exited the market after costly marketing efforts, leading to a 70% drop in the stock price of Miaokelan Duo, with Mengniu taking full control [1] Group 5 - Zijin Mining has invested an additional 28 billion in overseas acquisitions, projecting a profit of 51 billion by 2025, with its market value stabilizing above 1 trillion [1] - Hunan Gold's restructuring of 2.7 billion in assets aims to increase resource reserves, benefiting from rising prices of antimony and tungsten, resulting in record profits exceeding 1.27 billion [1] - A shareholder named Yu Han was penalized over 1 billion for manipulating stock prices, while Doctor's Optical spent 50 million on traffic acquisition but only 3 million on R&D [1] Group 6 - SAIC-GM-Wuling's debt ratio has risen to 85.24%, despite a 20.5% increase in sales, which remains 53.5 thousand units below its peak [1]

Core Viewpoint - Changchun High-tech, a leading company in the growth hormone industry, is experiencing a significant decline in net profit, with a forecasted drop of 91.48% to 94.19% for 2025 compared to the previous year [1] Group 1: Financial Performance - In the third quarter of 2025, Changchun High-tech reported a revenue of 9.807 billion yuan, a decrease of 5.6% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year [1] - The peak net profit for Changchun High-tech was 4.532 billion yuan in 2023, but it fell by 43% in 2024, indicating a continuing downward trend into 2025 [1] - The company anticipates a net profit of 150 million to 200 million yuan for 2025, marking a substantial decline from previous years [1] Group 2: Market and Product Dynamics - The sales of growth hormones are influenced by the number of adolescents and newborns, with increased competition also impacting performance [2] - Changchun High-tech's long-acting growth hormone and related products have been included in the new national medical insurance directory, effective January 1, 2026, with a price reduction of approximately 75% [2] - The company has adjusted its sales policies and pricing in response to industry policy changes and market conditions, which has contributed to reduced revenue and net profit [2] Group 3: Subsidiary Performance - Changchun High-tech's subsidiary, Baike Biological, is expected to report a net loss of 220 million to 280 million yuan for 2025, marking its first loss since going public, primarily due to intensified competition and decreased vaccination willingness [3] - The sales revenue of the shingles vaccine from Baike Biological has already seen a decline of 71.54% in 2024, continuing to be negatively affected in 2025 [4] - Factors affecting the shingles vaccine sales include public awareness of the disease, vaccination willingness, and increased market competition, leading to unsold inventory and returns [4]

Core Viewpoint - Changchun High-tech's 2025 performance forecast indicates a significant decline in key financial metrics, with net profit expected to drop by 91.48%-94.19% compared to 2024, reflecting ongoing challenges in the company's operations [1][2]. Financial Performance - The company anticipates a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, a drastic decrease from 2.583 billion yuan in 2024 [1][2]. - The non-recurring net profit is projected to decline by 82.09%-84.56%, with basic earnings per share shrinking from 6.42 yuan to between 0.37 yuan and 0.55 yuan [1][2]. - For the first three quarters of 2024, the company reported a revenue of 9.807 billion yuan, down 5.60% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year, indicating worsening performance in the fourth quarter [2]. Business Challenges - The decline in performance is attributed to multiple pressures, including pricing adjustments in the growth hormone business following its inclusion in the medical insurance catalog, ongoing losses from subsidiary Baike Biology, and high costs associated with R&D and new product market cultivation [2][3]. - The growth hormone business, which is a key revenue driver, faces significant profit margin compression due to new pricing policies and increased competition from generic drug manufacturers [5][6]. Market Dynamics - The inclusion of long-acting growth hormone in the national medical insurance catalog is seen as a double-edged sword; while it expands patient access, it also necessitates price reductions that adversely affect profit margins [5][6]. - The competitive landscape has intensified, with the market no longer dominated by JinSai Pharmaceuticals, leading to increased pricing pressure and reduced profit contributions from the growth hormone segment [6][12]. Innovation and Strategic Initiatives - Despite short-term pressures, JinSai Pharmaceuticals is advancing its innovation and internationalization strategies, with multiple new product approvals and collaborations aimed at expanding market reach [3][8]. - The company has submitted an H-share listing application to the Hong Kong Stock Exchange, aiming to enhance financing channels and support its growth strategy [11]. - Significant R&D investments are being made, with R&D expenses reaching 1.733 billion yuan in the first three quarters of 2025, representing a 22.96% increase year-on-year [9][12]. Future Outlook - The successful commercialization of innovative products, such as JinBeiXin® and MeiShiYa®, which have been included in the medical insurance catalog, is expected to drive revenue growth and offset declines in traditional segments [9][12]. - The internationalization strategy, including partnerships and market expansion efforts, is anticipated to open new growth avenues and enhance the company's competitive position in the global market [11][12].

Core Viewpoint - The company, Changchun High-tech (SZ000661), has issued a shocking earnings forecast for 2025, predicting a significant decline in net profit compared to the previous year, primarily due to increased R&D expenses, adjustments in sales strategies following the inclusion of long-acting growth hormone products in the national medical insurance catalog, and losses from its subsidiary [2][3]. Group 1: Earnings Forecast - For 2025, the company expects a net profit attributable to shareholders between 150 million to 220 million yuan, a drastic decrease of 91.48% to 94.19% from 2.583 billion yuan in 2024 [2]. - The forecasted net profit excluding non-recurring items for 2025 is estimated to be between 437 million to 507 million yuan, down 82.09% to 84.56% from 2.830 billion yuan in the previous year [2]. Group 2: Reasons for Profit Decline - The decline in profit is attributed to multiple factors, including increased R&D expenses as several products enter clinical stages and higher sales expenses for promoting new products [3]. - The company adjusted its sales strategies and pricing for long-acting growth hormone products after they were included in the national medical insurance catalog, which negatively impacted revenue and profit [3]. - Losses from the subsidiary, Changchun Baike Biotechnology Co., further contributed to the overall decline in performance [3]. Group 3: Market Position and Challenges - The company holds a 100% market share in the pegylated recombinant human growth hormone injection and a 68.4% market share in short-acting growth hormone products, indicating a strong competitive position [4]. - However, starting in 2024, the company began experiencing a downward trend in performance, with revenues and net profits decreasing by 7.55% and 43.01%, respectively, in 2024 [5]. - The introduction of price reductions for growth hormones in 2025 is expected to exert additional pressure on revenue growth [5]. Group 4: Strategic Initiatives - The company is increasing its R&D investment, which rose by 23% to 1.733 billion yuan in the first three quarters of 2025, representing 17.68% of total revenue [5]. - A recent business development transaction with Yarrow Bioscience, Inc. is expected to yield significant future payments, although these revenues will not be recognized in the 2025 financial statements [6]. - The company is also focusing on expanding its overseas market presence and has submitted an application for listing on the Hong Kong Stock Exchange to support this initiative [6].

Core Viewpoint - Changchun High-tech expects a significant decline in net profit for 2025, projecting between 150 million to 220 million yuan, attributed to increased R&D and sales expenses, as well as strategic adjustments in product delivery to mitigate potential impairment losses [1][2]. Group 1: Financial Performance - The company anticipates a net profit drop for 2025 compared to the previous year, with a forecast of 150 million to 220 million yuan [1]. - Increased R&D expenses and sales costs are impacting short-term profitability, as the company invests in new product development and market promotion [2][3]. - Adjustments in product sales policies and pricing, in response to industry changes and market conditions, have also contributed to reduced revenue and net profit [2]. Group 2: R&D and Product Development - Changchun High-tech is focusing on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions in oncology, respiratory, and immune-related fields [2]. - The company is actively increasing R&D investments, with several new products entering clinical stages, which is expected to yield long-term benefits despite short-term financial pressures [3]. - The company aims to enhance its R&D efficiency and develop sustainable long-term capabilities by exploring multi-line layouts and systemic solutions in various health sectors [3]. Group 3: Strategic Initiatives - Changchun High-tech is pursuing international expansion and has established a partnership with ALK for specific immunotherapy products, marking a significant step in the Chinese desensitization treatment market [3]. - The company is also planning to list in Hong Kong to strengthen its global strategy and enhance its financing capabilities, aiming to attract international investment for its clinical trials and R&D [4]. - The focus on building an innovative cooperation platform is part of the company's strategy to advance its international presence and drive growth [4].

Core Viewpoint - The approval of Rongpei growth hormone injection by the National Medical Products Administration (NMPA) marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in China, offering a long-acting alternative that has demonstrated superior efficacy compared to daily injections [1][2]. Company Summary - Weisheng Pharmaceutical's Rongpei growth hormone is the first and only long-acting growth hormone in China that has passed phase III clinical trials, showing a higher annualized growth rate compared to daily formulations [1]. - The product is expected to enhance the company's brand presence in the Greater China region, leveraging its clinical validation in the U.S. and successful phase III trial results in the Chinese population [2]. - The company plans to adopt a dual approach for market entry, focusing on both original imports and future local production partnerships [9]. Industry Summary - The Chinese growth hormone market has seen rapid growth, expanding from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, projected to reach 28.6 billion yuan by 2030 [4]. - The market is transitioning from volume expansion to value competition, with long-acting growth hormones expected to dominate the market by 2030, capturing 80% of the market share [4][5]. - The competitive landscape is characterized by a shift towards long-acting formulations, with existing players facing challenges from price competition and the need for differentiation [5][10]. Market Dynamics - The approval of Rongpei growth hormone is anticipated to provide a more convenient treatment option for pediatric patients, potentially increasing market penetration in a segment that has historically lagged behind developed countries [2]. - The market is experiencing a structural change, with a growing emphasis on long-acting products, which are expected to become a significant segment of the market [5][9]. - The pricing landscape is evolving, with recent price adjustments for long-acting growth hormones aimed at improving accessibility and creating a divide between "insurance-inclusive" and "high-end quality" segments [8][9]. Technological Advantages - Rongpei growth hormone utilizes TransCon technology, which allows for a slow release of growth hormone that mimics the natural structure of human growth hormone, providing a theoretical safety advantage over other long-acting products [6][7]. - The product's mechanism of action involves both indirect (80% via IGF-1) and direct pathways (20% directly on growth plates), enhancing its efficacy in promoting height growth [7]. Challenges Ahead - Despite its technological advantages, the commercialization of Rongpei growth hormone faces challenges, particularly regarding pricing and reimbursement issues, as many families are concerned about out-of-pocket costs [8][10]. - The company must navigate hospital access barriers and the evolving reimbursement landscape, which could impact the product's market penetration [8][9].